MEDI misses Street EPS

MedImmune (MEDI) reported EPS for the fourth quarter of $0.45, missing the Street consensus estimate by a penny. The company recorded revenues of $293 million, up from $238 million in the same period a year ago. The increase in revenues was mainly derived from an increase in sales of MEDI's respiratory syncytial virus (RSV) treatment Synagis, which came in at $250 million. ...